Fixed-Dose Combination Products with Chlorthalidone and ACE Inhibitors
Yes, fixed-dose combination medications containing chlorthalidone and an ACE inhibitor exist and are clinically available, though they are less common than hydrochlorothiazide-based combinations.
Available Combinations
While multiple guidelines strongly support combining ACE inhibitors with thiazide-like diuretics 1, 2, the specific availability of chlorthalidone-ACE inhibitor fixed-dose combinations is limited compared to hydrochlorothiazide formulations. The 2003 JNC 7 guidelines 3 list numerous ACE inhibitor-diuretic combinations (benazepril-hydrochlorothiazide, lisinopril-hydrochlorothiazide, enalapril-hydrochlorothiazide, etc.), but notably none contain chlorthalidone paired with an ACE inhibitor.
Research evidence confirms that fixed-dose combinations containing chlorthalidone and angiotensin receptor blockers are in development 4, and newer formulations like azilsartan-chlorthalidone have been studied 5. However, the traditional pairing has been chlorthalidone with beta-blockers (atenolol-chlorthalidone) rather than ACE inhibitors 3.
Clinical Implications
The practical reality is that most fixed-dose ACE inhibitor-diuretic combinations use hydrochlorothiazide, not chlorthalidone. For example:
- Lisinopril-hydrochlorothiazide is widely available in multiple dose combinations 3, 6
- The FDA label for lisinopril specifically mentions adding hydrochlorothiazide 12.5 mg when blood pressure is not controlled 7
Why This Matters
This is clinically significant because chlorthalidone is superior to hydrochlorothiazide for cardiovascular outcomes. The 2017 Hypertension Canada guidelines 1 emphasize that thiazide-like diuretics (chlorthalidone and indapamide) resulted in an additional 12% risk reduction for cardiovascular events and 21% risk reduction in heart failure compared with thiazide diuretics. Chlorthalidone provides greater 24-hour blood pressure reduction than hydrochlorothiazide 1 and demonstrated superior outcomes in major trials like ALLHAT 8.
Practical Approach
For your 58-year-old patient with uncontrolled hypertension, you have two evidence-based options:
Use separate tablets: Chlorthalidone 12.5-25 mg plus lisinopril (or another ACE inhibitor) as individual medications. This allows optimal dosing of the superior diuretic.
Use available fixed-dose combinations: Lisinopril-hydrochlorothiazide fixed-dose combination, accepting that hydrochlorothiazide is less potent than chlorthalidone 9.
The first option is preferable given chlorthalidone's superior cardiovascular outcomes 1, 10, despite requiring two pills instead of one. The 2013 ESH/ESC guidelines 2 strongly favor fixed-dose combinations for adherence, but this benefit must be weighed against using a less effective diuretic component.
Important Monitoring
If using chlorthalidone, monitor closely for:
- Hypokalemia: Chlorthalidone carries higher risk than hydrochlorothiazide (adjusted HR 3.06) 9
- Hypomagnesemia: Also more common with chlorthalidone 9
- Renal function: Particularly important when combined with ACE inhibitors 7
The combination of ACE inhibitor plus thiazide-like diuretic remains a Class I, Level A recommendation across all major guidelines 2, 11, making this an excellent choice for stage 2 hypertension regardless of whether you use a fixed-dose or separate-pill approach.